Incidence of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates that test susceptible to cephalosporins and aztreonam by the revised CLSI breakpoints.
The incidence of aztreonam and cephalosporin susceptibility, determined using the revised CLSI breakpoints, for extended-spectrum-β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolates was evaluated. Our analysis showed that results for aztreonam and/or ≥1 cephalosporin were reported as susceptible or intermediate for 89.2% of ESBL-producing E coli isolates (569/638 isolates) and 67.7% of ESBL-producing K. pneumoniae isolates (155/229 isolates).
North Shore-LIJ Health System, Division of Infectious Diseases, Department of Medicine, Manhasset, New York, USA carla.s.mcwilliams@gmail.com.
Carla S
CS
McWilliams
North Shore-LIJ Health System Laboratories, Department of Pathology and Laboratory Medicine, Lake Success, New York, USA.
Susan
S
Condon
North Shore-LIJ Health System, Department of Population Health, Great Neck, New York, USA Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA.
Rebecca M
RM
Schwartz
North Shore-LIJ Health System Laboratories, Department of Pathology and Laboratory Medicine, Lake Success, New York, USA Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA.
Christine C
CC
Ginocchio
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects* / Q000201:enzymology*; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology; D006801:Humans; D015994:Incidence; D007710:Klebsiella Infections / Q000453:epidemiology / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects* / Q000201:enzymology*; D008826:Microbial Sensitivity Tests; D001618:beta-Lactamases / Q000378:metabolism
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D001618:beta-Lactamases; D001398:Aztreonam